Idelalisib + rituximab good value for relapsed/refractory CLL
- 期刊名称PharmacoEconomics & Outcomes News
- 卷第745卷
- 期第1期
- 印刷ISSN1173-5503
- 电子ISSN1179-2043
- 文件大小164.37KB
- 发表时间2016-1
- DOI10.1007/s40274-016-2758-1
- 页码17-17
同期刊推荐
Aztreonam tops tobramycin in CFPharmacoEconomics & Outcomes News · 2012
Warfarin prophylaxis justified in nonvalvular AFPharmacoEconomics & Outcomes News · 1998
Antiretrovirals in HIV infectionPharmacoEconomics & Outcomes News · 1999
Fidaxomicin value for money&NA; · PharmacoEconomics & Outcomes News · 2012
Diclofenac&NA; · PharmacoEconomics & Outcomes News · 2006
SMC accepts use of IluvienFarash, Mohammad Sabzinejad; Attari, Mahmoud Ahmadian · PharmacoEconomics & Outcomes News · 2014
Getting value from health insurance plansPharmacoEconomics & Outcomes News · 2014
Screening and decolonisation ofS.PharmacoEconomics & Outcomes News · 2014